Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Macrophage polarization in chronic kidney disease: a balancing act between renal recovery or decline?

Engel JE, Chade AR.

Am J Physiol Renal Physiol. 2019 Sep 30. doi: 10.1152/ajprenal.00380.2019. [Epub ahead of print]

PMID:
31566432
2.

Targeted VEGF (Vascular Endothelial Growth Factor) Therapy Induces Long-Term Renal Recovery in Chronic Kidney Disease via Macrophage Polarization.

Engel JE, Williams E, Williams ML, Bidwell GL 3rd, Chade AR.

Hypertension. 2019 Nov;74(5):1113-1123. doi: 10.1161/HYPERTENSIONAHA.119.13469. Epub 2019 Sep 23.

PMID:
31542966
3.

Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Guise E, Engel JE, Williams ML, Mahdi F, Bidwell GL 3rd, Chade AR.

Am J Physiol Renal Physiol. 2019 May 1;316(5):F1016-F1025. doi: 10.1152/ajprenal.00607.2018. Epub 2019 Mar 20.

PMID:
30892933
4.

Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM.

Hypertension. 2019 Jun;73(6):e87-e120. doi: 10.1161/HYP.0000000000000090.

5.

Understanding and managing atherosclerotic renovascular disease: still a work in progress.

Chade AR.

F1000Res. 2018 Nov 29;7. pii: F1000 Faculty Rev-1862. doi: 10.12688/f1000research.16369.1. eCollection 2018. Review.

6.

Performance of Patients with Early Parkinson Disease on an Executive and Social Cognition Battery.

Esteves S, Gleichgerrcht E, Torralva T, Chade A, Gómez Arévalo G, Gershanik O, Manes F, Roca M.

Cogn Behav Neurol. 2018 Sep;31(3):142-150. doi: 10.1097/WNN.0000000000000159.

PMID:
30239464
7.

Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-like Polypeptide.

Kuna M, Mahdi F, Chade AR, Bidwell GL 3rd.

Sci Rep. 2018 May 21;8(1):7923. doi: 10.1038/s41598-018-24897-9.

8.

A translational model of chronic kidney disease in swine.

Chade AR, Williams ML, Engel J, Guise E, Harvey TW.

Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F364-F373. doi: 10.1152/ajprenal.00063.2018. Epub 2018 Apr 25.

9.

Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients.

Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Valkovic P, Goetz CG, Stebbins GT.

Parkinsonism Relat Disord. 2018 Jul;52:83-89. doi: 10.1016/j.parkreldis.2018.03.027. Epub 2018 Mar 28.

PMID:
29625875
10.

Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy.

Stefani A, Heidbreder A, Brandauer E, Guaita M, Neier LM, Mitterling T, Santamaria J, Iranzo A, Videnovic A, Trenkwalder C, Sixel-Döring F, Wenning GK, Chade A, Poewe W, Gershanik OS, Högl B.

Sleep. 2018 Jun 1;41(6). doi: 10.1093/sleep/zsy053.

11.

VEGF therapy for the kidney: emerging strategies.

Guise E, Chade AR.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F747-F751. doi: 10.1152/ajprenal.00617.2017. Epub 2018 Feb 14. Review.

12.

Systemic biopolymer-delivered vascular endothelial growth factor promotes therapeutic angiogenesis in experimental renovascular disease.

Chade AR, Williams ML, Guise E, Vincent LJ, Harvey TW, Kuna M, Mahdi F, Bidwell GL 3rd.

Kidney Int. 2018 Apr;93(4):842-854. doi: 10.1016/j.kint.2017.09.029. Epub 2017 Dec 19.

13.

Enhanced maximal exercise capacity, vasodilation to electrical muscle contraction, and hind limb vascular density in ASIC1a null mice.

Drummond HA, Xiang L, Chade AR, Hester R.

Physiol Rep. 2017 Aug;5(15). pii: e13368. doi: 10.14814/phy2.13368.

14.

Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Foltynie T, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Aviles-Olmos I, Benchetrit E, Benoit C, Bergareche-Yarza A, Cervantes-Arriaga A, Chade A, Cormier F, Datieva V, Gallagher DA, Garretto N, Gdovinova Z, Gershanik O, Grofik M, Han V, Huang J, Kadastik-Eerme L, Kurtis MM, Mangone G, Martinez-Castrillo JC, Mendoza-Rodriguez A, Minar M, Moore HP, Muldmaa M, Mueller C, Pinter B, Poewe W, Rallmann K, Reiter E, Rodriguez-Blazquez C, Singer C, Tilley BC, Valkovic P, Goetz CG, Stebbins GT.

Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.

15.

Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.

Chade AR.

Hypertension. 2017 Apr;69(4):551-563. doi: 10.1161/HYPERTENSIONAHA.116.08319. Epub 2017 Feb 13. Review. No abstract available.

16.

A kidney-selective biopolymer for targeted drug delivery.

Bidwell GL 3rd, Mahdi F, Shao Q, Logue OC, Waller JP, Reese C, Chade AR.

Am J Physiol Renal Physiol. 2017 Jan 1;312(1):F54-F64. doi: 10.1152/ajprenal.00143.2016. Epub 2016 Oct 26.

17.

Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity.

Chade AR, Hall JE.

Am J Nephrol. 2016;44(5):354-367. Epub 2016 Oct 22. Review.

18.

Decreased Palpebral Fissure in Patients with Parkinson's Disease.

Sanchez Abraham M, Gomez Arevalo G, Garcia SS, Mizraji G, Chade A, Gershanik O.

Mov Disord Clin Pract. 2016 Mar 24;4(1):58-61. doi: 10.1002/mdc3.12346. eCollection 2017 Jan-Feb.

19.

Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.

Harvey TW, Engel JE, Chade AR.

Am J Nephrol. 2016;43(2):74-84. doi: 10.1159/000444719. Epub 2016 Mar 2.

20.

Focal Task-specific Dystonia among Professional Musicians in Latin America.

Gatto E, Chade A, Persi G, Parisi V, Ayarza A, Campuzano M, García S.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 3;5:295. doi: 10.7916/D8XS5T5D. eCollection 2015.

21.

Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct.

Chade AR, Tullos NA, Harvey TW, Mahdi F, Bidwell GL 3rd.

J Am Soc Nephrol. 2016 Jun;27(6):1741-52. doi: 10.1681/ASN.2015040346. Epub 2015 Nov 5.

22.

Verbal Fluency as a Rapid Screening Test for Cognitive Impairment in Early Parkinson's Disease.

Torralva T, Laffaye T, Báez S, Gleichgerrcht E, Bruno D, Chade A, Ibañez A, Manes F, Gershanik O, Roca M.

J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):244-7. doi: 10.1176/appi.neuropsych.14060139. Epub 2015 Jun 12.

PMID:
26067437
23.

Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?

Chade AR.

J Am Soc Nephrol. 2016 Jan;27(1):1-3. doi: 10.1681/ASN.2015050491. Epub 2015 Jun 2. No abstract available.

24.

Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease.

Furlong M, Tanner CM, Goldman SM, Bhudhikanok GS, Blair A, Chade A, Comyns K, Hoppin JA, Kasten M, Korell M, Langston JW, Marras C, Meng C, Richards M, Ross GW, Umbach DM, Sandler DP, Kamel F.

Environ Int. 2015 Feb;75:144-50. doi: 10.1016/j.envint.2014.11.002. Epub 2014 Nov 21.

25.

Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.

Tullos NA, Stewart NJ, Davidovich R, Chade AR.

Nephrol Dial Transplant. 2015 Apr;30(4):584-93. doi: 10.1093/ndt/gfu361. Epub 2014 Nov 21.

26.

Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.

Chade AR, Tullos N, Stewart NJ, Surles B.

J Am Soc Nephrol. 2015 May;26(5):1071-80. doi: 10.1681/ASN.2014040323. Epub 2014 Nov 6.

27.

Nephron Deficiency and Predisposition to Renal Injury in a Novel One-Kidney Genetic Model.

Wang X, Johnson AC, Williams JM, White T, Chade AR, Zhang J, Liu R, Roman RJ, Lee JW, Kyle PB, Solberg-Woods L, Garrett MR.

J Am Soc Nephrol. 2015 Jul;26(7):1634-46. doi: 10.1681/ASN.2014040328. Epub 2014 Oct 27.

28.

Subjective visual vertical in Pisa syndrome.

Scocco DH, Wagner JN, Racosta J, Chade A, Gershanik OS.

Parkinsonism Relat Disord. 2014 Aug;20(8):878-83. doi: 10.1016/j.parkreldis.2014.04.030. Epub 2014 May 9.

PMID:
24857768
29.

Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.

Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, Alvarez-Sánchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martínez-Castrillo JC, Mendoza-Rodríguez A, Moore HP, Rodríguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.

Eur J Neurol. 2014 Mar;21(3):519-24. doi: 10.1111/ene.12349. Epub 2014 Jan 21.

PMID:
24447695
30.

Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.

Chade AR, Stewart NJ, Peavy PR.

Kidney Int. 2014 Apr;85(4):833-44. doi: 10.1038/ki.2013.477. Epub 2013 Dec 18.

31.

Dietary fat intake, pesticide use, and Parkinson's disease.

Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, Sandler DP, Tanner CM.

Parkinsonism Relat Disord. 2014 Jan;20(1):82-7. doi: 10.1016/j.parkreldis.2013.09.023. Epub 2013 Oct 1.

32.

C-peptide preserves the renal microvascular architecture in the streptozotocin-induced diabetic rat.

Flynn ER, Lee J, Hutchens ZM Jr, Chade AR, Maric-Bilkan C.

J Diabetes Complications. 2013 Nov-Dec;27(6):538-47. doi: 10.1016/j.jdiacomp.2013.07.002. Epub 2013 Aug 29.

33.

The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease.

Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG, Martinez-Martin P.

Parkinsonism Relat Disord. 2013 Oct;19(10):889-93. doi: 10.1016/j.parkreldis.2013.05.017. Epub 2013 Jun 19.

PMID:
23791519
34.

Renal vascular structure and rarefaction.

Chade AR.

Compr Physiol. 2013 Apr;3(2):817-31. doi: 10.1002/cphy.c120012. Review.

35.

Primary proteasome inhibition results in cardiac dysfunction.

Herrmann J, Wohlert C, Saguner AM, Flores A, Nesbitt LL, Chade A, Lerman LO, Lerman A.

Eur J Heart Fail. 2013 Jun;15(6):614-23. doi: 10.1093/eurjhf/hft034. Epub 2013 Apr 24.

36.

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.

Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.

Eur J Neurol. 2015 Jan;22(1):37-43. doi: 10.1111/ene.12165. Epub 2013 Apr 22.

PMID:
23607783
37.

Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis.

Eirin A, Zhu XY, Li Z, Ebrahimi B, Zhang X, Tang H, Korsmo MJ, Chade AR, Grande JP, Ward CJ, Simari RD, Lerman A, Textor SC, Lerman LO.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):1006-13. doi: 10.1161/ATVBAHA.113.301164. Epub 2013 Feb 21.

38.

Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Chade AR, Stewart N.

J Am Soc Hypertens. 2013 Mar-Apr;7(2):180-90. doi: 10.1016/j.jash.2013.01.004. Epub 2013 Feb 19. Review.

39.

Renoprotective effects of hepatocyte growth factor in the stenotic kidney.

Stewart N, Chade AR.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F625-33. doi: 10.1152/ajprenal.00504.2012. Epub 2012 Dec 26.

40.

Genetic modification of the association of paraquat and Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM.

Mov Disord. 2012 Nov;27(13):1652-8. doi: 10.1002/mds.25216. Epub 2012 Oct 8.

41.

Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.

J Neurol. 2013 Jan;260(1):228-36. doi: 10.1007/s00415-012-6624-1. Epub 2012 Aug 5.

PMID:
22865238
42.

Early superoxide scavenging accelerates renal microvascular rarefaction and damage in the stenotic kidney.

Kelsen S, He X, Chade AR.

Am J Physiol Renal Physiol. 2012 Aug 15;303(4):F576-83. doi: 10.1152/ajprenal.00154.2012. Epub 2012 May 23.

43.

Motor-language coupling: direct evidence from early Parkinson's disease and intracranial cortical recordings.

Ibáñez A, Cardona JF, Dos Santos YV, Blenkmann A, Aravena P, Roca M, Hurtado E, Nerguizian M, Amoruso L, Gómez-Arévalo G, Chade A, Dubrovsky A, Gershanik O, Kochen S, Glenberg A, Manes F, Bekinschtein T.

Cortex. 2013 Apr;49(4):968-84. doi: 10.1016/j.cortex.2012.02.014. Epub 2012 Mar 8.

PMID:
22482695
44.

The relationship between executive functions and fluid intelligence in Parkinson's disease.

Roca M, Manes F, Chade A, Gleichgerrcht E, Gershanik O, Arévalo GG, Torralva T, Duncan J.

Psychol Med. 2012 Nov;42(11):2445-52. doi: 10.1017/S0033291712000451. Epub 2012 Mar 22.

45.

Effect of the anti-oxidant tempol on fetal growth in a mouse model of fetal growth restriction.

Stanley JL, Andersson IJ, Hirt CJ, Moore L, Dilworth MR, Chade AR, Sibley CP, Davidge ST, Baker PN.

Biol Reprod. 2012 Jul 26;87(1):25, 1-8. doi: 10.1095/biolreprod.111.096198. Print 2012 Jul.

46.

Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach.

Chade AR, Kelsen S.

Am J Physiol Renal Physiol. 2012 May 15;302(10):F1342-50. doi: 10.1152/ajprenal.00674.2011. Epub 2012 Feb 22.

47.

VEGF: Potential therapy for renal regeneration.

Chade AR.

F1000 Med Rep. 2012;4:1. doi: 10.3410/M4-1. Epub 2012 Jan 3.

48.

Comparing the Neuropsychiatric Profile of Patients with Alzheimer Disease Who Present Spared versus Impaired Executive Functioning.

Gleichgerrcht E, Chade A, Torralva T, Roca M, Manes F.

Curr Gerontol Geriatr Res. 2011;2011:514059. doi: 10.1155/2011/514059. Epub 2011 Oct 26.

49.

Solvent exposures and Parkinson disease risk in twins.

Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, Tanner CM.

Ann Neurol. 2012 Jun;71(6):776-84. doi: 10.1002/ana.22629. Epub 2011 Nov 14.

50.

Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat.

Maric-Bilkan C, Flynn ER, Chade AR.

Am J Physiol Renal Physiol. 2012 Feb 1;302(3):F308-15. doi: 10.1152/ajprenal.00421.2011. Epub 2011 Oct 26.

Supplemental Content

Support Center